Actively Recruiting
Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer
Led by ShiCang Yu · Updated on 2023-01-09
80
Participants Needed
1
Research Sites
224 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project plans to use CIK combined with chemotherapy, immunotherapy and targeted therapy to treat CRC patients, so as to explore the effectiveness of CIK treatment and the CRC subtypes more suitable for CIK treatment, thereby improving the survival rate and quality of life of CRC patients.
CONDITIONS
Official Title
Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Diagnosed with colorectal cancer, TNM stage III-IV
- At least one measurable tumor lesion outside the brain according to RECIST 1.1 criteria
- Have failed or relapsed after one or two prior standard therapies, or are intolerant to or voluntarily stopped one or two prior standard therapies
- Expected survival of at least 90 days
- Major organs functioning normally
- Voluntarily agree to participate, sign informed consent, and cooperate with follow-up
You will not qualify if you...
- Participated in other drug clinical trials within 4 weeks before the study
- Uncontrolled hypertension with blood pressure above 140/90 mmHg under a single antihypertensive agent
- History of myocardial ischemia or infarction (grade I or higher), arrhythmia (grade I or higher), or cardiac dysfunction
- History of substance abuse or mental disorders preventing abstinence
- Presence of uncontrolled infections requiring antibiotic treatment
- At enrollment, prior chemotherapy-caused hematologic toxicity grade 2 or higher, or non-hematologic toxicity grade 3 or higher
- Known history of HIV, hepatitis B (HBsAg positive), or hepatitis C virus (anti-HCV positive) infection
- Presence of any indwelling catheter or drain except dedicated central venous catheter
- Presence of brain metastases or history of CNS diseases such as seizures, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or autoimmune CNS disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Southwest Hospital, Army Medical University (Third Military Medical University)
Chongqing, Chongqing Municipality, China, 400038
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here